XML 50 R38.htm IDEA: XBRL DOCUMENT v3.10.0.1

Segments: (Tables)

9 Months Ended

Sep. 30, 2018

Segment information

a. Segment information:

		North America								Europe								International Markets
		Three months ended September 30,
		2018				2017				2018				2017				2018				2017
		(U.S. $ in millions)
Revenues		$	2,265			$	3,043			$	1,212			$	1,380			$	726			$	882
Gross profit			1,232				1,833				683				721				301				351
R&D expenses			158				230				62				101				21				35
S&M expenses			301				325				249				289				120				158
G&A expenses			128				149				74				90				37				51
Other income (loss)			(4	)			(1	)			1				—				—				(3	)
Segment profit		$	649			$	1,130			$	297			$	241			$	123			$	110
		North America								Europe								International Markets
		Nine months ended September 30,
		2018				2017				2018				2017				2018				2017
		(U.S. $ in millions)
Revenues		$	7,059			$	9,452			$	3,982			$	4,016			$	2,265			$	2,485
Gross profit			3,867				5,971				2,211				2,147				942				1,043
R&D expenses			528				777				208				312				70				129
S&M expenses			902				1,158				741				864				384				503
G&A expenses			357				432				243				258				115				144
Other income			(206	)			(82	)			(1	)			(15	)			(11	)			(4	)
Segment profit		$	2,286			$	3,686			$	1,020			$	728			$	384			$	271

		Three months ended September 30,								Nine months ended September 30,
		2018				2017				2018				2017
		(U.S. $ in millions)								(U.S. $ in millions)
North America profit		$	649			$	1,130			$	2,286			$	3,686
Europe profit			297				241				1,020				728
International Markets profit			123				110				384				271
Total segment profit			1,069				1,481				3,690				4,685
Profit (loss) of other activities			35				(11	)			87				3
			1,104				1,470				3,777				4,688
Amounts not allocated to segments:
Amortization			297				357				909				1,088
Other asset impairments, restructuring and other items			658				550				2,080				1,209
Goodwill impairment			—				—				300				6,100
Gain on divestitures, net of divestitures related costs			(31	)			—				(114	)			—
Inventory step-up			—				—				—				67
Other R&D expenses			60				150				82				176
Costs related to regulatory actions taken in facilities			1				(1	)			6				48
Legal settlements and loss contingencies			19				(20	)			(1,239	)			324
Other unallocated amounts			84				56				226				143
Consolidated operating income (loss)			16				378				1,527				(4,467	)
Financial expenses, net			229				259				736				704
Consolidated income (loss) before income taxes		$	(213	)		$	119			$	791			$	(5,171	)

Schedule of Net Sales by Product Line

Segment revenues by major products and activities:

The following tables present revenues by major products and activities for the nine and three months ended September 30, 2018 and 2017:

		Three months ended								Nine months ended
		September 30,								September 30,
		2018				2017				2018				2017
		(U.S. $ in millions)								(U.S. $ in millions)
North America segment
Generic products		$	922			$	1,233			$	2,957			$	3,979
COPAXONE			463				819				1,403				2,475
BENDEKA / TREANDA			161				179				502				498
ProAir			107				155				352				399
QVAR			36				83				173				265
AUSTEDO			62				6				136				8
Distribution			333				294				984				864
		Three months ended								Nine months ended
		September 30,								September 30,
		2018				2017				2018				2017
		(U.S. $ in millions)								(U.S. $ in millions)
Europe segment
Generic products		$	845			$	871			$	2,749			$	2,543
COPAXONE			124				150				417				440
Respiratory products			93				90				312				258
		Three months ended								Nine months ended
		September 30,								September 30,
		2018				2017				2018				2017
		(U.S. $ in millions)								(U.S. $ in millions)
International Markets segment
Generic products		$	498			$	629			$	1,523			$	1,720
COPAXONE			14				18				52				65
Distribution			149				146				456				406

X

- Definition

Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8924-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599

+ Details

Name:	us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599

+ Details

Name:	us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration